Guggenheim Maintains Buy on Krystal Biotech, Lowers Price Target to $189

Benzinga · 05/07 15:23
Guggenheim analyst Debjit Chattopadhyay maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and lowers the price target from $195 to $189.